Biomarin Pharmaceutical Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript

Apr 04, 2023 / 03:20PM GMT
Debjit D. Chattopadhyay - Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology

Good morning, and thank you for joining us on day 2 of Guggenheim genomic medicines at our Disease Conference. I am Debjit the therapeutic analyst at Guggenheim. My privilege to host Brian Mueller, BioMarin's Executive VP and Chief Financial Officer. Thank you for your time today, Brian.

Brian R. Mueller - BioMarin Pharmaceutical Inc. - CFO & Executive VP

Thanks, Debjit. Appreciate you having us.

Debjit D. Chattopadhyay - Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology

Awesome. So before we get started with the Q&A, do you want to spend a minute just walking people through BioMarin now that the company needs any introduction.

Brian R. Mueller - BioMarin Pharmaceutical Inc. - CFO & Executive VP

Yes, absolutely. Thanks for the opportunity. I've got some opening remarks. I'd love to share, really appreciate the opportunity to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot